# EDGAR Filing Document

**Accession Number:** 0001385508
**File Stem:** 0001385508-23-000069
**Filing Date:** 2023-3
**Character Count:** 8362
**Document Hash:** 067ed5a1488f01c731aaf0745214dee6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001385508-23-000069.hdr.sgml**: 20230303

**ACCESSION NUMBER**: 0001385508-23-000069

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230302

**FILED AS OF DATE**: 20230303

**DATE AS OF CHANGE**: 20230303

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** CRYSTAL ROGER
- **CENTRAL INDEX KEY:** 0001656633

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38193
- **FILM NUMBER:** 23701899

**MAIL ADDRESS:**
- **STREET 1:** 445 PARK AVE
- **STREET 2:** 10TH FL.
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OPIANT PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001385508
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 464744124
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 233 WILSHIRE BLVD
- **STREET 2:** SUITE 400
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90401
- **BUSINESS PHONE:** (310) 598-5410

**MAIL ADDRESS:**
- **STREET 1:** 233 WILSHIRE BLVD
- **STREET 2:** SUITE 400
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90401

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Lightlake Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20091009

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Madrona Ventures, Inc.
- **DATE OF NAME CHANGE:** 20070108

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>CRYSTAL ROGER<br><sub>(Last) (First) (Middle)</sub><br>C/O OPIANT PHARMACEUTICALS, INC.<br>233 WILSHIRE BLVD, SUITE 400<br><sub>(Street)</sub><br>SANTA MONICA, CA 90401<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>OPIANT PHARMACEUTICALS, INC. [ OPNT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-03-02 |  | D<sup>(1)</sup> |  | 37438 | D | $20 | 37901 | D |  |
| Common Stock | 2023-03-02 |  | D<sup>(2)</sup> |  | 37901 | D | $20 | 0 | D |  |
| Common Stock par value $0.001 | 2023-03-02 |  | D<sup>(1)</sup> |  | 5100 | D | $20 | 0 | D |  |
| Common Stock | 2023-03-02 |  | A<sup>(3)</sup> |  | 6667 | A | $0 | 6667 | D |  |
| Common Stock | 2023-03-02 |  | D<sup>(4)</sup> |  | 6667 | D | $20 | 0 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Option | $6.0 | 2023-03-02 |  | D<sup>(5)</sup> |  |  | 25000 | 2013-12-31 | 2023-12-30 | Common Stock | 25000.0 | $0 | 0 | D |  |
| Option | $5.0 | 2023-03-02 |  | D<sup>(5)</sup> |  |  | 150000 | 2014-06-15 | 2024-06-14 | Common Stock | 150000.0 | $0 | 0 | D |  |
| Option | $7.25 | 2023-03-02 |  | D<sup>(5)</sup> |  |  | 375000 | 2015-10-27 | 2025-10-26 | Common Stock | 375000.0 | $0 | 0 | D |  |
| Option | $6.0 | 2023-03-02 |  | D<sup>(5)</sup> |  |  | 25000 | 2013-12-31 | 2023-12-30 | Common Stock | 25000.0 | $0 | 0 | D |  |
| Stock Option (right to buy) | $14.62 | 2023-03-02 |  | D<sup>(5)</sup> |  |  | 13200 | <sup>(5)</sup> | 2029-01-14 | Common Stock | 13200.0 | $0 | 0 | D |  |
| Common Stock | $13.6 | 2023-03-02 |  | D<sup>(5)</sup> |  |  | 27250 | <sup>(5)</sup> | 2030-01-07 | Common Stock | 27250.0 | $0 | 0 | D |  |
| Stock Option (right to buy) | $12.15 | 2023-03-02 |  | D<sup>(5)</sup> |  |  | 31250 | <sup>(5)</sup> | 2031-01-26 | Common Stock | 31250.0 | $0 | 0 | D |  |

---

### Footnotes:

(1) Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").

(2) Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 37,901 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.

(3) 6,667 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer.

(4) Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 6,667 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement.

(5) The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.

**Signature:** /s/ Roger Crystal  
**Date:** 2023-03-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**